Man Group’s Aquestive Therapeutics AQST Stock Holding History

Man Group’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-29,213	Closed	-$189K	–	2380
2025 Q4	$189K	Buy	+29,213	New	+$182K	﹤0.01%	2132
2024 Q3	–	Sell	-12,653	Closed	-$32.9K	–	1959
2024 Q2	$32.9K	Sell	12,653 -209,433	-94%	-$700K	﹤0.01%	1987
2024 Q1	$946K	Buy	+222,086	New	+$739K	﹤0.01%	1562
2023 Q3	–	Sell	-128,547	Closed	-$221K	–	1855
2023 Q2	$212K	Buy	+128,547	New	+$233K	﹤0.01%	1809
2023 Q1	–	Sell	-89,900	Closed	-$81.1K	–	2064
2022 Q4	$81.1K	Hold	89,900	–	–	﹤0.01%	1932
2022 Q3	$105K	Buy	+89,900	New	+$102K	﹤0.01%	1846
2022 Q2	–	Sell	-89,900	Closed	-$120K	–	1945
2022 Q1	$235K	Buy	89,900 +71,383	+385%	+$208K	﹤0.01%	1871
2021 Q4	$72K	Buy	+18,517	New	+$92.9K	﹤0.01%	1895

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Man Group's AQST Position: Q1 2026 in Review

Man Group sold out of Aquestive Therapeutics (AQST) in Q1 2026, closing a stake of 29,213 shares — an estimated $189K sold.

Man Group first reported a position in AQST in Q4 2021 and held it in 8 quarters. The position peaked at $946K in Q1 2024. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

Man Group reported no remaining Aquestive Therapeutics position as of Q1 2026 after selling out during the quarter.
Man Group sold 29,213 Aquestive Therapeutics shares in Q1 2026, an estimated $189K.
Man Group first reported a position in Aquestive Therapeutics in Q4 2021 and held it in 8 quarters.
Man Group's Aquestive Therapeutics position peaked at $946K in Q1 2024.
179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.